Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial
Blood (2018) 132 (Supplement 1): 959.
Currently there are no citedby results. Try again later.
